Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. by Giese, Coralie et al.
1www.eurosurveillance.org
Rapid communications
Injection of new psychoactive substance snow blow 
associated with recently acquired HIV infections among 
homeless people who inject drugs in Dublin, Ireland, 
2015
C Giese 1 2 , D Igoe 2 , Z Gibbons 3 , C Hurley 4 , S Stokes 3 , S McNamara 3 , O Ennis 4 , K O’Donnell 2 , E Keenan 3 , C De Gascun 5 6 , F 
Lyons 7 , M Ward 4 , K Danis 1 8 , R Glynn 4 , A Waters 5 , M Fitzgerald 4 , on behalf of the outbreak control team 9 
1. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, 
(ECDC), Stockholm, Sweden
2. HSE Health Protection Surveillance Centre, Dublin, Ireland
3. HSE National Drug Treatment Centre, Dublin, Ireland
4.  Department of Public Health, Dublin, Ireland
5. National Virus Reference Laboratory, University College Dublin, Dublin, Ireland
6. School of Medicine, University College Dublin, Dublin, Ireland
7. St. James’s Hospital, Dublin, Ireland
8.  French Institute for Public Health Surveillance (Institut de Veille Sanitaire, InVS), Paris, France
9. The members of the team are listed at the end of the article
Correspondence: Coralie Giese (coraliegiese@hotmail.com)
Citation style for this article: 
Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, Ennis O, O’Donnell K, Keenan E, De Gascun C, Lyons F, Ward M, Danis K, Glynn R, Waters A, Fitzgerald 
M. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, 
Ireland, 2015. Euro Surveill. 2015;20(40):pii=30036. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.40.30036 
Article submitted on 01 October 2015 / accepted on 08 October 2015 / published on 08 October 2015
In February 2015, an outbreak of recently acquired HIV 
infections among people who inject drugs (PWID) was 
identified in Dublin, following similar outbreaks in 
Greece and Romania in 2011. We compared drug and 
risk behaviours among 15 HIV cases and 39 controls. 
Injecting a synthetic cathinone, snow blow, was asso-
ciated with recent HIV infection (AOR: 49; p = 0.003). 
Prevention and control efforts are underway among 
PWID in Dublin, but may also be needed elsewhere in 
Europe.
Background
In February 2015, the Department of Public Health 
(DPH), Health Service Executive (HSE) in Dublin, 
Ireland, identified an unexpected increase in cases 
of acute HIV infection among people who inject drugs 
(PWID); three cases were diagnosed p24 antigen-posi-
tive in January and February 2015, compared with two 
cases diagnosed during the whole year in 2014 [1]. 
Drug treatment clinicians had also identified increased 
use of a new psychoactive substance (NPS) alpha-
pyrrolidinovalerophenone (α-PVP), known as snow 
blow, which was being used by ‘chaotic’ PWID, and 
which they suspected might be linked to the increase 
[2]. Clinicians defined the chaotic group as homeless 
PWID who, if on opioid substitution treatment (OST), 
required daily attendance at their treatment pro-
gramme, due to continued use of a variety of other 
illicit substances in an intensive or chaotic way. We 
undertook an epidemiological investigation to identify 
the likely source of this increase.
Epidemiological investigation and case 
definition
Clinicians in Dublin provided information on mode 
of transmission for new HIV diagnoses, and notified 
new HIV diagnoses in PWID immediately to the DPH. 
Clinicians asked all cases about the use of snow blow 
and at-risk sexual practices and whether they were 
homeless. Cases were crosschecked with data from the 
Dublin Region Homeless Executive’s accommodation 
client database for periods of accommodation between 
1 October 2013 and 30 June 2015.
We defined a case as HIV diagnosis in PWID in Dublin 
reporting first HIV-positive test since January 2014: a 
confirmed case had recent HIV infection (one or more 
of: p24 antigen-positive, history of negative HIV test 
within 12 months of first positive test, acute serocon-
version illness, or recency assay test); a probable case 
had an HIV diagnosis of unknown duration but with an 
epidemiological link (sexual intercourse or drug shar-
ing) to a confirmed case. We excluded cases with no 
evidence of recent infection or epidemiological links to 
recent HIV diagnoses, and cases previously diagnosed 
abroad.
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Case–control study 
We conducted a case–control study among chaotic 
PWID, injecting within the previous 12 months, residing 
in Dublin and diagnosed since July 2014. We included 
confirmed and probable cases. A list of HIV test-nega-
tive (within three months) PWID attending the National 
Drug Treatment Centre (NDTC) in Dublin, registered by 
NDTC as homeless and requiring daily attendance due 
to chaotic behaviour, was generated. A random sample 
was taken from this list, using random figures gener-
ated from Excel. Patients on this list who attended and 
agreed to participate, were included. We conducted 
face-to-face or telephone interviews, to collect infor-
mation on drug use including frequency of use, sexual 
and injecting at-risk practices, and living conditions. 
Participants were asked to report exposures for 12 
months before HIV positive diagnosis (cases) or neg-
ative diagnosis (controls). To examine associations 
between exposures and infection, we calculated 
adjusted odds ratios (OR) and 95% confidence inter-
vals (CI) using multiple logistic regression. Inclusion 
criteria used were p<0.2 for model entry. 
Laboratory investigations
HIV serological diagnosis was based on the Abbott 
Architect HIV Ag/Ab Combo, Biomerieux VIDAS HIV 
Duo Ultra and P24II, and Fujirebio INNO-LIA HIV I/II 
SCORE assays; recency testing was performed on the 
Sedia Biosciences HIV-1 LAg-Avidity EIA; and HIV-1 RNA 
testing was performed on the Abbott Molecular m2000 
Figure 1
Number of recent HIV infections or diagnoses with epidemiological link to recent infections in PWID in Dublin, by month 
of first diagnosis, January 2014 to September 2015a (n = 38) 
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Demographic and social characteristics Case Control P value
n n
Sex Female 6 6 0.05
Place of residencea
Home/relatives 7 14
0.36
Homeless/hostels 7 25
Prison 4 0 0.001
Median (range) Median (range) P value 
Age (years) 35 (25–51) 33 (19–51) 0.87
Age at first injection (years) 17 (11–39) 20 (11–44) 0.14
Duration of injection (years) 16 (3–26) 11 (0–39) 0.14
Table 1
Distribution of demographic and social characteristics between cases (n=15) and controls (n=39), case–control study, 
outbreak of recent HIV infection in PWID, Dublin, Ireland, 2015
PWID: people who inject drugs.
a In the previous 12 months.
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RealTime system. HIV subtyping has been described 
elsewhere [3].
Urine samples of cases attending NDTC were screened 
by the NDTC laboratory using an in-house Liquid 
Chromatography/Mass Spectrometry (LC/MS) NPS 
screening method. Since 2008, the laboratory of the 
NDTC has regularly redeveloped its methods in order 
to meet the challenge of testing for NPS by adding new 
drugs as they appear in Europe [4,5]. For the purposes 
of the study, the laboratory of the NDTC developed a 
tailored NPS LC/MS screening method targeting 26 
NPS drugs and common amphetamines in urine. The 
method covered all relevant drugs detected in the 
laboratory in recent years including α-PVP which was 
first added to the NPS screen in 2011. 
Results
Epidemiological investigation and case–control 
study
In 2014 and 2015, 38 confirmed and probable cases 
of HIV subtype B were reported (32 confirmed and 
six probable) (Figure). Among these, 16 were female; 
median age was 35 years (range: 24–51). Since January 
2014, 29 of the 38 had been registered with homeless 
accommodation services, seven were not registered, 
and information was not available for two. All females 
and 13 of the 20 males with information available, 
Factors positively associated with recent HIV infection
Cases Controls
Crude 
OR (95% CI) P valuen
(N = 15) 
n
(N = 39)
Drugs Administration
Methamphetaminea Injecting 7 1 33 (3.2–1535) < 0.001
Snow blowa Injecting 13 7 30 (4.7–300) < 0.001
Snow blow (frequency)a
Injecting daily 8 1b 128 (10–1,595) < 0.001
Injecting occasionally 5 6b 13 (2.1–85) 0.006
Amphetaminesc Using 3 1 9.5 (0.66–511) 0.03
Other head shop drugsc Using 3 1 9.5 (0.66–511) 0.03
Benzodiazepinesc Using 13 23 4.5 (0.82–46) 0.05
Crackc Injecting 1 1 3.6 (0.19–64) 0.39
Other 7 13 1.9 (0.55–6.67) 0.3
Heroinc Injecting 13 38 0.17 (0.003–3.7) 0.12
Cocainec
Injecting 3 3 3.1 (0.54–18) 0.21
Other 2 5 1.2 (0.21–7.4) 0.81
Opiatesc
Injecting 0 2 NC NC NC
Other 1 2 1.3 (0.10–15) 0.86
Sexual practices
Sex with PWID d 10 15 3.8 (0.87–19) 0.041
Had sex d 10 25 1.3 (0.29–6.8) 0.7
Sex while high d,e 7 21 0.67 (0.08–8.9) 0.68
Unprotected sexe 8 22 0.55 (0.05–7.8) 0.54
At-risk injecting practices
Use of used needles or syringes 8 2 21 (3.1–225) < 0.001
Use of used filters 6 5 4.5 (0.89–23) 0.026
Use of used containers or spoons for mixingd 8 10 3.7 (0.86–16) 0.038
Median (range) Median (range)
Number of different drugs used 5 (1-9) 3 (1-7) 1.7f (1.1–2.6) 0.011
Number of people with whom shared or reused works 1 (0-15) 0 (0-10) 1.2f (0.97–1.5) 0.09
Table 2
Factors positively associated with recent HIV infection in PWID in univariate analysis, case–control study, outbreak of 
recent HIV infection in PWID, Dublin, Ireland, 2015
CI: confidence interval; NC: Not calculable; OR: odds ratio.
a Reference: not injecting in the previous 12 months or other route of administration.
b Five missing values.
c Reference: not using in the previous 12 months.
d One missing value.
e Among those who had sex.
f Per additional unit increase.
4 www.eurosurveillance.org
were homeless. In all 18 of the 20 PWID with informa-
tion available, reported injecting snow blow. At-risk 
practices, namely sex with PWID, or sex with an HIV-
positive partner were reported by 20 of the 38 cases. 
Thirteen cases reported both using snow blow and 
sexual at-risk practices. One death was reported.
We recruited 15 cases (12 confirmed, three probable) 
of 24 cases and 39 controls. Cases were interviewed 
between 25 May and 18 August 2015 at infectious dis-
ease clinics (n=5), drug clinics (n=7), in prison (n=2) or 
by telephone (n=1). Controls were interviewed at NDTC. 
All participants but one were enrolled in methadone 
maintenance treatment.
Cases did not differ from controls in terms of age, age 
at first injection, duration of injection or living circum-
stances (Table 1). Females were more likely to become 
infected than males.
Compared with controls, cases were more likely to have 
reported injecting methamphetamine, snow blow, con-
suming amphetamines, other head shop drugs (‘legal 
highs’) or benzodiazepines (through various routes of 
administration) (Table 2).
All cases who reported injecting methamphetamine 
also reported injecting snow blow. Compared with 
those who did not inject in the previous 12 months, the 
odds of recent HIV infection was higher among PWIDs 
who reported occasional use (weekly, monthly or less 
than a month) and highest in those who reported 
injecting snow blow daily (Table 2).
Compared with controls, cases were more likely to 
have reused needles or syringes, to have used several 
types of drugs in the previous 12 months and to have 
had sex with PWID partners.
In the multivariable model, injecting snow blow, using 
used needles/syringes, and having sex with PWID were 
the only exposures which remained independently 
associated with HIV (Table 3).
Drug analysis
Urine samples from 12 cases in the case–control study 
were tested for NPS. Five were positive: α-PVP (n = 4), 
α-PVP and MDPBP (n = 1); seven were negative.
Discussion
This investigation among homeless chaotic PWID in 
Dublin is the first evidence of an association between 
injecting snow blow and recent HIV infection, with daily 
snow blow injectors being at highest risk. The epide-
miological findings are supported by the detection of 
α-PVP in the urine of cases. Snow blow has been found 
to contain α-PVP, a second generation cathinone and 
is closely related to MDPV with similar abuse liability 
[2,4,6]. These findings are consistent with the known 
stimulant effects of synthetic cathinones and at-risk 
injecting practices linked to their use [6-11]. Drug 
treatment clinicians raised concerns that clients who 
injected snow blow generally exhibited more chaotic 
behaviours, leading to dis-inhibition, more sharing of 
needles and syringes, and unprotected sex.
Between 2005 and 2014, more than 81 synthetic cathi-
none derivatives were reported to the European Union 
(EU) Early Warning System [12]. Significant quantities of 
NPS are seized annually in Ireland [13]. In 2011, α-PVP 
was first detected in urine samples tested for NPS by 
NDTC. Urines tested for NPS in 2015 contain predomi-
nantly α-PVP, pentedrone and MDPBP [5].
Use of synthetic cathinones by homeless chaotic PWID 
populations has previously been reported in Ireland 
and in Europe [6,14]. In Dublin, there are more than 
500 homeless PWID, a significant population at risk of 
HIV infection [15]. At the time of the study, 252 of ca 
520 attendees at the NDTC (48.5%) were homeless. The 
general situation regarding homelessness in Dublin has 
also deteriorated significantly over 2014 and 2015, with 
a 28% increase in the number of individuals accessing 
emergency accommodation in Dublin in the 12 months 
to June 2015 [16]. The NDTC has a remit for providing 
OST for homeless PWID, but responding adequately to 
the needs of these PWID remains challenging.
In Dublin, measures taken include multi-disciplinary 
work to engage HIV-positive PWID in HIV care and, 
where appropriate, on antiretroviral therapy: offering 
HIV testing to PWID; awareness raising among clients, 
clinicians and networks of PWID about injecting head 
shop drugs such as snow blow, sexual at-risk behav-
iours and of the need to engage with methadone and 
treatment services. Services have been enhanced 
in terms of contact tracing and active case finding 
Factors positively associated with recent HIV infection Adjusted odds ratio 95% confidence intervals P value
Injecting snow blow 49 3.6–669 0.003
Reusing needles /syringes 13 1.01–177 0.049
Having sex with PWID 36 1.6–782 0.022
Female sex 3.5 0.27–44 0.34
Table 3
Factors positively associated with recent HIV infection in multiple regression analysis, case–control study, outbreak of 
recent HIV infection in PWID, Dublin, Ireland, 2015
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and provision of greater access to needle exchange 
services by strengthening needle/syringe provision 
through outreach.
There were limitations in undertaking this investiga-
tion. Cases and controls were difficult to recruit among 
homeless chaotic PWID, exposed to illegal and at-risk 
behaviours. In the descriptive epidemiology, homeless 
status was determined by asking the patients if they 
were homeless, and by crosschecking with the home-
less service database. If however homeless persons 
didn’t register for any homeless service they might not 
have been identified as homeless. For the analytical 
study, controls identified by NDTC as homeless and 
chaotic were included in the study. However, we found 
that the homeless status of some participants had 
changed with a minority no longer reporting homeless-
ness, although all remained chaotic. Cases were more 
likely to have been in prison. However this was subject 
to selection bias as we did not select controls in pris-
ons but included cases who were in prison. Behavioural 
findings were based on self-reported information and 
some participants were under the effect of drugs while 
interviewed. This may have had altered the accuracy of 
measurement of past exposures.
Ireland is the third country reporting an outbreak of 
HIV among PWID within the past five years in Europe, 
after Greece and Romania in 2011 [14,17]. A similar 
increase has also recently been reported in Glasgow 
and Clyde in June 2015 [18]. Outbreaks of HIV among 
PWID have also been reported in Israel in 2012 and in 
Indiana, United States, in early 2015 [19,20]. With low 
coverage of harm reduction activities such as needle 
and syringe programmes and OST in most European 
countries, and a growth of the market in new psychoac-
tive substances, in particular the detection of α -PVP in 
the 28 EU Member States, the risk of HIV among PWID, 
and particularly homeless chaotic PWID is likely to be 
increasing in Europe [2,12,21]. It may be of benefit for 
other countries to consider strengthening prevention 
programmes for PWID [21-23].
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